2023
A phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+ patients with previously treated advanced non-uveal melanoma (TEBE-AM).
Davar D, Ikeguchi A, Buchbinder E, Shoushtari A, Seedor R, Bernicker E, Weiss S, Daniels G, Panella T, Ryan H, Goodall H, Sullivan R. A phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+ patients with previously treated advanced non-uveal melanoma (TEBE-AM). Journal Of Clinical Oncology 2023, 41: tps9594-tps9594. DOI: 10.1200/jco.2023.41.16_suppl.tps9594.Peer-Reviewed Original ResearchMetastatic cutaneous melanomaMetastatic uveal melanomaAdvanced melanomaInvestigator's choicePrimary endpointDual primary endpointsOverall survival benefitPhase 3 trialSimilar patient populationsPhase 2/3 trialIC armOS benefitPrior ipilimumabRECIST responseInhibitor regimenSupportive careSurvival benefitCare therapyAnti-CTLA4CtDNA levelsTumor burdenInvestigational agentsPatient populationCutaneous melanomaClinical trials
2015
Dabrafenib for the treatment of melanoma
Weiss S, Pavlick A. Dabrafenib for the treatment of melanoma. Expert Opinion On Orphan Drugs 2015, 3: 1075-1084. DOI: 10.1517/21678707.2015.1067136.Peer-Reviewed Original ResearchAdvanced melanomaBrain metastasesBRAF V600EEffective salvage therapyMilestone clinical trialsPractice-changing approachAdvanced melanoma patientsHigh tumor burdenMelanoma brain metastasesFirst-line therapyMajority of patientsMEK inhibitor trametinibBRAF inhibitor therapyTreatment of melanomaV600K mutationsMutant BRAF kinaseMechanism of actionSalvage therapyAdverse eventsInhibitor therapyMelanoma patientsTumor burdenPoor prognosisCancer symptomsIL-2